Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial Designed to Assess the Efficacy and Safety of Ciclesonide Applied as a Nasal Spray at Three Dose Levels (200 Mcg, 100 Mcg, or 25 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 6-11 Years of Age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Dec 2016
Price :
$35
*
At a glance
- Drugs Ciclesonide (Primary)
- Indications Allergic rhinitis
- Focus Therapeutic Use
- Sponsors ALTANA Pharma; AstraZeneca
- 29 May 2012 New trial record